This refers to the use of two monoclonal antibodies - casirivimab and imdevimab. When used together, they bind to the adhesive protein SARS-CoV-2, blocking the virus's ability to infect cells.
According to the study, the use of these antibodies should primarily be applied to critically ill patients requiring lung ventilation, as well as to patients in whom antibodies do not develop.
Doctors say these antibodies reduce the risk of hospitalization and shorten the duration of symptoms in patients at highest risk of serious illness.
Meanwhile, Novavax and the Serum Institute of India have applied to the World Health Organization for the use of the Novavax vaccine against coronavirus in emergencies.
"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world," said Novavax President and CEO Stanley C. Erck.